Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at < 4 years of age with phenylketonuria: results of the 3-year extension of the SPARK open-label, multicentre…

Overview of attention for article published in Orphanet Journal of Rare Diseases, August 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (55th percentile)
Above-average Attention Score compared to outputs of the same age and source (62nd percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 13 Dimensions

Readers on

mendeley: 31 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 3,194 followers.

BH4 cofactor treatment for PKU children younger than 4 years https://t.co/0jPtcno0Xo

Reply Repost Favourite

@macdonj https://t.co/2pz2Or2eqI #openaccess support the #altmetric

Reply Repost Favourite

Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at https://t.co/BQdxUuptud

Reply Repost Favourite

Long-term efficacy and safety of sapropterin in patients who initiated sapropterin at https://t.co/vVfaUvrO1d

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.